Phase 2Recruiting
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Randomized Phase 2 Trial of Ruxolitinib in Combination With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma.
- Sponsor
- Baptist Health South Florida (Academic or other)
- Enrolment
- 190 planned
- Conditions
- Glioblastoma; Brain Cancer; Glioblastoma Multiforme; Glioblastoma Multiforme of Brain; Glioblastoma Multiforme, Adult; MGMT-Unmethylated Glioblastoma; MGMT-Methylated Glioblastoma
- Interventions
- Ruxolitinib; Temozolomide; Radiation Therapy
- Ages
- adults, older adults
- Registry
- NCT06991101
From the registry
The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to take the study drug ruxolitinib in addition to the standard of care temozolomide and radiation therapy and the other half will be assigned to the standard of care temozolomide and radiation therapy only. This assignment will be randomized in a 1-to-1 ratio, like the flip of a coin.
Primary outcomes
- Overall survival (OS) at end of study